The Breast Unit Database (BRENDA) captures breast patients' clinical data and
tracks their ongoing survival rates. This data is benchmarked against
established key performance indicators in the field. By comparing our
performance to these benchmarks, we can identify areas for improvement and
ensure the Breast Surgery Unit is delivering the highest quality of care.
BRENDA goes beyond traditional clinical data by capturing Patient-Reported
Outcome Measures (PROMs). PROMs are standardised questionnaires that ask
patients about their experiences and well-being after treatment. Research has
consistently shown that regularly evaluating PROMs leads to improved patient
care, outcomes and quality of life.
In our own clinical experience at SVHM, PROMs have proven to be invaluable
tools. The data they provide allows our surgeons and clinicians to personalise
care for each patient. By pinpointing specific areas of need identified through
PROMs, we can tailor treatment plans to better address each patient's unique
circumstance and priorities.
Overall, BRENDA serves as a powerful platform and clinical tool for continuous
improvement in breast cancer care at SVHM, aligning with the principles of
value-based healthcare. By leveraging both clinical data and patient-reported
experiences, BRENDA empowers us to deliver the most effect and personalised
care possible for our patients.
Since its launch in January 2023, the Breast Unit Database (BRENDA) has data from over 270 patients already entered into the system. The completion rate for patient-reported outcome measures (PROMs), which serves as a vital clinical tool for our Breast Surgeons, is around 60-70%, which sits at a higher than the expected rate for this type of collection method. This enables our Breast Surgeons to personalise and optimise breast cancer treatments, streamline processes, and minimize side effects, providing our patients with the best possible care and outcomes.
The BRENDA database represents a pioneering effort at SVHM in the field of breast cancer research, facilitating the collection of comprehensive patient data and PROMS, which will undoubtedly lead to a more in-depth understanding of breast cancer treatment and its outcomes.